title: [The effect and safety of tirofiban on acute ST segment elevation myocardial infarction patients receiving no early reperfusion therapy].
abstract: OBJECTIVE
  To study the efficacy and safety of tirofiban on acute ST segment elevation myocardial infarction (STEMI) in patients who do not receive early reperfusion therapy.
  
  
  METHODS
  A total of 153 STEMI patients without early reperfusion therapy were randomly distributed into tirofiban group (therapeutic group, n=78) and non-tirofiban group (control group, n=75). Coronary angiography was performed on the 5(th) and 10(th) day after treatment, and percutaneous coronary intervention (PCI) was conducted when necessary. The differences of initial patency of the infarct related artery (IRA), bleeding complication and clinic events within 30 days between these two groups were compared.
  
  
  RESULTS
  Tirofiban did not increase the percentage of patients with initial patency of IRA (60.3% vs 64.0%, P=0.63). The percentage of patients with thrombolysis in myocardial infarction (TIMI) 3 after PCI was 100.0% in tirofiban group and 97.1% in the control group (P=0.09). However, application of tirofiban significantly decreased poor myocardial perfusion rate after PCI (1.4% vs 8.8%, P=0.04). No significant differences were observed in major adverse cardiovascular events (MACE) (3.8% vs 2.7%, P=0.68) between therapeutic and control group. The same is true for mild (5/78 vs 4/75 cases, P=0.78) and severe hemorrhage (2/78 vs 1/75 cases, P=0.58), and severe thrombocytopenia (2/78 vs 0/75 cases, P=0.10) between these two groups within 30 days.
  
  
  CONCLUSIONS
  Tirofiban did not increase initial patency in STEMI patients without early reperfusion therapy. However, it can improve myocardial perfusion after PCI.
authors.forename: D P
authors.initials: DP
authors.lastname: Zhang
authors.forename: L F
authors.initials: LF
authors.lastname: Wang
authors.forename: H S
authors.initials: HS
authors.lastname: Wang
authors.forename: L
authors.initials: L
authors.lastname: Xu
authors.forename: W M
authors.initials: WM
authors.lastname: Li
authors.forename: Z H
authors.initials: ZH
authors.lastname: Ni
authors.forename: K
authors.initials: K
authors.lastname: Xia
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Heart Center, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing 100020, China.
authors.forename: X C
authors.initials: XC
authors.lastname: Yang
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D017023:Coronary Angiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000072657:ST Elevation Myocardial Infarction; D012449:Safety; D055502:Secondary Prevention; D000077466:Tirofiban; D016896:Treatment Outcome; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D014443:Tyrosine; D000077466:Tirofiban